Home/Pipeline/Coronary Artery Bypass Grafts

Coronary Artery Bypass Grafts

Coronary artery disease

Pre-clinicalActive

Key Facts

Indication

Coronary artery disease

Phase

Pre-clinical

Status

Active

Company

Vascudyne

About Vascudyne

Vascudyne is a private, pre-revenue tissue engineering company pioneering the development of fully biological, regenerative vascular grafts and soft tissue biomaterials. Its core technology platform is designed to produce non-immunogenic human tissues for cardiovascular, vascular, neurological, wound care, and aesthetic applications. The company is currently advancing its investigational allograft technology toward clinical trials, supported by a team and advisors with deep expertise in medical device development and regulatory pathways for Class III implants.

View full company profile

Therapeutic Areas

Cardiovascular Vascular Surgery Wound Care Aesthetic Medicine

Other Coronary artery disease Drugs

Drug	Company	Phase	Status
MUTI™ Drug‑Eluting Stent	Meril	Commercial	Active
Premier DES	Relisys Medical Devices	Commercial	Active
Release R DES	Relisys Medical Devices	Commercial	Active
Pristine DES	Relisys Medical Devices	Commercial	Active
BioMatrix family (Flex/Alpha)	Biosensors International	Commercial	Marketed
Coronary Artery Disease Program	Elixir Medical	Pre-clinical	Active
Essential pro Stent	iVascularU	Post-Market	Active
FGF-1	Zhittya Genesis Medicine	Phase 2	Active
OMT-28	OMEICOS Therapeutics	Phase 2	Planned
Fantom Encore	REVA Medical	Commercial	Active
Next-Gen Drug-Eluting Stents	Translumina	Development	Active
Geographic Market Expansion	Translumina	Commercial	Active